Quantile estimation following non-parametric phase I clinical trials with ordinal response

Statistics in Medicine

Volumn 23, Issue 16, 2004, Pages 2483-2495

  Paul, Ranjan K ^a,b   Rosenberger, William F ^b,c   Flournoy, Nancy ^d  

^a BOEING COMPANY   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

Common toxicity criteria; Isotonic regression; Phase I clinical trials; Proportional odds model; Random walk rules; Sequential design

Indexed keywords

ACCURACY; ACUTE LEUKEMIA; ARTICLE; BAYES THEOREM; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; EXPERIMENTAL DESIGN; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MAXIMUM LIKELIHOOD METHOD; NONPARAMETRIC TEST; ONCOLOGY; RATING SCALE; REGRESSION ANALYSIS; RISK ASSESSMENT; SEQUENTIAL ANALYSIS; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TOXICITY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; LEUKEMIA; MAXIMUM TOLERATED DOSE; QUINOLONES; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 4344611668     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1834     Document Type: Article

References (17)

1. World Health Organization. Common Toxicity Criteria, Version 2.0. Washington: World Health Organization, 2000.
2. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Statistics in Medicine 2002; 21:2757-2770.
3. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A comparison of two phase I clinical trial designs. Statistics in Medicine 1994; 13:1799-1806.
4. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
5. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998; 17:1103-1120.
6. Durham SD, Flournoy N. Random walks for quantile estimation. In Statistical Decision Theory and Related Topics, vol. V. Gupta SS, Berger JO (eds). New York: Springer, 1994; 467-476.
7. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for phase I clinical trials. Biometrics 1997; 53:745-760.
8. Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002; 58:171-177.
9. Leung DH, Wong Y. An improved up-and-down design for phase I clinical trials. Controlled Clinical Trials 2001; 22:126-138.
10. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 1997; 89:1138-1147.
11. Gordon NH, Willson JKV. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Statistics in Medicine 1992; 11:2063-2075.
12. Paul R. Random walk rules for clinical trials under non-standard conditions. Doctoral Thesis, University of Maryland Graduate School, Baltimore, 2001.
13. McCullagh P, Nelder JA. Generalized Linear Models. Cambridge University Press: Cambridge, 1983.
14. Perevozskaya I, Rosenberger WF, Haines LM. Optimal design for the proportional odds model. Canadian Journal of Statistics 2003; 31:225-235.
15. Albert A, Anderson, JA. On the existence of maximum likelihood estimates in logistic regression models. Biometrika 1984; 71:1-10.
16. Robertson T, Wright FT, Dykstra RL. Order Restricted Statistical Inference. Wiley: New York, 1988.
17. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97:3361-3369.